The information provided on EL7.AI is for educational and informational purposes only and does not constitute financial advice.
The information provided on EL7.AI is for educational and informational purposes only and does not constitute financial advice.
Sign in to access this content
Sign InKamada Ltd. (NASDAQ: KMDA) announced today that its plasma collection center in San Antonio, Texas, has received official approval from the U.S. Food and Drug Administration (FDA). The regulatory milestone follows a successful on-site inspection conducted by the FDA in February 2026, marking a significant boost to the company's operational capacity. This approval allows the facility to contribute directly to the company’s supply chain for its portfolio of plasma-derived biopharmaceuticals. Kamada, which is also listed on the Tel Aviv Stock Exchange, aims to strengthen its internal production capabilities through this expansion to support treatments for rare and serious medical conditions. Investors and analysts view this operational progress as a positive step in securing long-term supply chain stability. The move aligns with the company's broader strategy to enhance vertical integration within the biotech sector.